Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
© 2021. The Author(s)..
The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox's multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Biomarker research - 9(2021), 1 vom: 29. Okt., Seite 78 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Einama, Takahiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 01.11.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s40364-021-00335-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332542211 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332542211 | ||
| 003 | DE-627 | ||
| 005 | 20231225215801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40364-021-00335-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332542211 | ||
| 035 | |a (NLM)34715925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Einama, Takahiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.11.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox's multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a CA125/MUC16 | |
| 650 | 4 | |a Co-expression | |
| 650 | 4 | |a Mesothelin | |
| 700 | 1 | |a Yamagishi, Yoji |e verfasserin |4 aut | |
| 700 | 1 | |a Takihata, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Takafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamasaki, Tamio |e verfasserin |4 aut | |
| 700 | 1 | |a Hirose, Yuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yonamine, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Fujinuma, Ibuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tsunenari, Takazumi |e verfasserin |4 aut | |
| 700 | 1 | |a Koga, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ishibashi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nagata, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Shiraishi, Takehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaki, Toshimitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Shinto, Eiji |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Kimi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Kimiya |e verfasserin |4 aut | |
| 700 | 1 | |a Ueno, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Kishi, Yoji |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuda, Hitoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomarker research |d 2013 |g 9(2021), 1 vom: 29. Okt., Seite 78 |w (DE-627)NLM230912753 |x 2050-7771 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:1 |g day:29 |g month:10 |g pages:78 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40364-021-00335-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 1 |b 29 |c 10 |h 78 | ||